Autoimmune Myopathies: Updates on Evaluation and Treatment.

摘要: The major forms of autoimmune myopathies include dermatomyositis (DM), polymyositis (PM), myositis associated with antisynthetase syndrome (ASS), immune-mediated necrotizing myopathy (IMNM), and inclusion body (IBM). While each these conditions has unique clinical histopathological features, they all share an component. These can occur in isolation or be systemic malignancies connective tissue disorders (overlap syndromes). As more been learned about conditions, it become clear that traditional classification schemes do not adequately group patients according to shared features prognosis. Newer classifications are now utilizing myositis-specific autoantibodies which correlate phenotypes risk malignancy, help offering prognostic information regard treatment response. Based on observational data expert opinion, corticosteroids considered first-line therapy for DM, PM, ASS, IMNM, although intravenous immunoglobulin (IVIG) is increasingly being used as initial IMNM related statin use. Second-line agents often required, but further prospective investigation required regarding the optimal choice timing agents.